BURBANK, Calif., June 29, 2021 (GLOBE NEWSWIRE) — by way of NewMediaWire – Medolife Rx, Inc. (“Medolife”), a worldwide built-in biopharmaceutical firm with R&D, manufacturing, and client product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), introduced at this time that it entered right into a partnership settlement with Xoles Del Pacifico, S.A. De C.V. (Xoles) a number one worldwide distributor of pharmaceutical and wellness merchandise, to convey Medolife’s client manufacturers to the Mexican market. Merchandise to be bought in Mexico by way of the settlement embrace Medolife’s Immunapen™ product line, in addition to its cannabidiol (CBD) and non-CBD line of ache aid/muscle lotions. Moreover, Medolife will use its patented polarization expertise to boost current over-the-counter (OTC) pharmaceutical-grade white label merchandise, corresponding to male enhancement merchandise and nutritional vitamins.
The unique partnership settlement grants Xoles the only real alternative to market and promote Medolife’s proprietary product line all through Mexico by way of its broad community with hundreds of retail areas, in addition to by way of varied direct-to-consumer e-commerce channels. Xoles has robust relationships all through the nation with the biggest drugstore chains and international huge field retailers. Distribution will embrace Medolife’s main product line, known as Immunapen™, that features 4 formulations particularly designed to advertise basic wellness elements of shoppers’ lives corresponding to sleep, immunity assist, anti-anxiety, and vitality and focus. This product line was created in response to the COVID-19 pandemic to handle well being considerations revolving round immunity, stress, anxiousness and lack of vitality. The Immunapen™ product line accommodates a pure model of the peptides used within the Firm’s lead drug candidate Escozine® which can be amplified by Medolife’s proprietary polarization expertise. Moreover, by way of the partnership, the 2 firms will collaborate on growth of further topical ache administration merchandise using the corporate’s polarization expertise that will increase the efficacy of identified pure compounds.
Past the Immunapen™ product line, the settlement consists of the sale and distribution of the Firm’s core wellness merchandise that embrace hemp-based CBD manufacturers, which have additionally been polarized to extend efficiency and efficacy. The primary merchandise to enter Mexico would be the CBD Muscle and Ache cream, with further merchandise following shortly, together with tinctures and sprays. The CBD market has continued to develop exponentially lately, with client adoption at all-time highs. The Mexican market presents a novel alternative for the Firm as it’s much less saturated than different extra established markets, giving Medolife first-mover benefit by way of this relationship.
“We have now been engaged on this settlement for a while now and I couldn’t be extra happy to see it signed and take impact,” stated Medolife CEO Dr. Arthur Mikaelian. “We have now such a robust portfolio of merchandise and proceed to search for companions who’ve the expertise in choose markets to capitalize on them. We have now discovered simply that in working with Xoles. Past their in depth retail distribution footprint, they perceive the wants of shoppers within the Mexican market, and, extra importantly, how you can attain them with the distinctive message of our merchandise. We hope that this relationship proves fruitful for each of our firms in addition to shoppers in Mexico.”
The Firm has been engaged on rebranding its nutraceutical division in latest months and hopes to launch this new branding within the close to time period. It should retain the rights to market and promote its merchandise all through the US, whereas in search of partnerships and joint ventures around the globe to expedite their distribution and make a worldwide impression.
Past its wellness merchandise, Medolife has scientific initiatives happening in each the US and the Dominican Republic (DR) on its lead drug candidate, Escozine®. Escozine® additionally makes use of a patented polarization expertise developed by Dr. Mikaelian that will increase the efficiency of single molecules and complicated compounds, on this case peptides derived from scorpions. The Firm has been scaling manufacturing of each its wellness and nutraceutical merchandise because it not too long ago renewed its product registration within the DR on Escozine® as a pure various remedy for varied types of most cancers. It has additionally accomplished a PRE-Investigational New Drug (PIND) submitting on Escozine®, by way of the US Meals and Drug Administration (FDA), and is awaiting a response on the submission of its closing information set.
About Medolife Rx
Medolife Rx, Inc. is a worldwide biotechnology firm with operations in scientific analysis, manufacturing, and client merchandise. Medolife Rx was created by way of the merger of Medolife, a non-public firm based by Dr. Arthur Mikaelian who pioneered the unlaying polarization expertise that makes the Firm’s portfolio of pharmaceutical and nutraceutical merchandise so efficient, and Quanta, Inc., a direct-to-consumer wellness product portfolio firm. The Firm’s lead scientific growth packages embrace Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Firm’s polarization expertise and is being researched as a remedy of varied indications, together with COVID-19 and most cancers. The Firm has accomplished preclinical security and efficacy analysis on Escozine® and is pursuing product registration and drug approval in varied international locations, together with the US and all through Latin America.
By its subsidiary QuantRx, Medolife manufactures and distributes client wellness merchandise in high-impact client areas corresponding to ache aid, magnificence, and basic wellness. QuantRx merchandise are designed utilizing Dr. Mikaelian’s polarization expertise, which applies advances in quantum biology to extend the efficiency of lively elements. Finally, Quanta’s mission is to ship higher, more practical elements to raise product efficacy, cut back waste, and facilitate more healthy, extra sustainable consumption.
Past its personal scientific and client purposes, the polarization expertise utilized by Medolife and its subsidiaries has many potential purposes. From potentiating bio-ingredients, to producing more-effective carbon-trapping vegetation, to transformative anti-aging options, Medolife has the chance to upend how industrial and pharmaceutical merchandise are made and enhance their advantages, whereas reducing their chemical focus.
Protected Harbor Assertion beneath the U.S. Personal Securities Litigation Reform Act of 1995: This launch accommodates statements which can be forward-looking in nature which specific the beliefs and expectations of administration together with statements concerning the Firm’s anticipated outcomes of operations or liquidity; statements regarding projections, predictions, expectations, estimates or forecasts as to our enterprise, monetary and operational outcomes and future financial efficiency; and statements of administration’s targets and aims and different comparable expressions regarding issues that aren’t historic details. In some circumstances, you possibly can establish forward-looking statements by terminology corresponding to “anticipate,” “estimate,” “plan,” “mission,” “persevering with,” “ongoing,” “anticipate,” “we imagine,” “we intend,” “might,” “will,” “ought to,” “may,” and comparable expressions. Such statements are based mostly on present plans, estimates and expectations and contain a lot of identified and unknown dangers, uncertainties and different elements that would trigger the Firm’s future outcomes, efficiency or achievements to vary considerably from the outcomes, efficiency or achievements expressed or implied by such forward-looking statements. These elements and extra data are mentioned within the Firm’s filings with the Securities and Trade Fee and statements on this launch needs to be evaluated in gentle of those necessary elements. Though we imagine that these statements are based mostly upon cheap assumptions, we can not assure future outcomes. Ahead-looking statements communicate solely as of the date on which they’re made, and the Firm undertakes no obligation to replace publicly or revise any forward-looking assertion, whether or not because of new data, future developments or in any other case.